Entry Point Capital, LLC Rocket Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 125,590 shares of RCKT stock, worth $383,049. This represents 0.17% of its overall portfolio holdings.
Number of Shares
125,590
Previous 301,053
58.28%
Holding current value
$383,049
Previous $737,000
44.5%
% of portfolio
0.17%
Previous 0.39%
Shares
4 transactions
Others Institutions Holding RCKT
# of Institutions
194Shares Held
96.4MCall Options Held
563KPut Options Held
418K-
Rtw Investments, LP New York, NY17.7MShares$53.9 Million0.77% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx8.47MShares$25.8 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.89MShares$21 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$18.9 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA3.9MShares$11.9 Million2.3% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $231M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...